Contact
searchSearch
HMP Global
Login

Alzheimer & Dementia Related Cognitive Disorders Topic Center

A person completes a puzzle of a profile of a head, with a piece missing from where the brain is located.
News
Alzheimer Disease Drugs Show Double the Impact in Long-Term Extension Results
08/05/2025
Jolynn Tumolo
Patients with early Alzheimer disease (AD) treated with lecanemab and donanemab experienced a higher degree of reduced cognitive decline in clinical trial extension studies compared with 18-month results from the core trials.
Patients with early Alzheimer disease (AD) treated with lecanemab and donanemab experienced a higher degree of reduced cognitive decline in clinical trial extension studies compared with 18-month results from the core trials.
Patients with early Alzheimer...
08/05/2025
Neurology
From Neurology
doctor holds clipboard of data and research
News
Limited Demographic Data Transparency Found in Evidence Supporting FDA-Authorized AI Devices for Alzheimer Treatment
07/30/2025
Maria Mantas
Researchers found limited demographic data transparency in the evidence supporting FDA-authorized artificial intelligence (AI)– and machine learning (ML)–enabled medical devices for the treatment of Alzheimer disease and related dementias.
Researchers found limited demographic data transparency in the evidence supporting FDA-authorized artificial intelligence (AI)– and machine learning (ML)–enabled medical devices for the treatment of Alzheimer disease and related dementias.
Researchers found limited...
07/30/2025
Psych Congress Network
FDA approval stamp
News
FDA Approves Modified Titration Dosing for Donanemab-azbt to Reduce ARIA-E Incidence in Early AD
07/10/2025
Maria Mantas
The US Food and Drug Administration (FDA) has approved a label update for donanemab-azbt (Kisunla), Eli Lilly and Company’s monthly intravenous amyloid-targeting therapy for adults with early symptomatic Alzheimer disease (AD).
The US Food and Drug Administration (FDA) has approved a label update for donanemab-azbt (Kisunla), Eli Lilly and Company’s monthly intravenous amyloid-targeting therapy for adults with early symptomatic Alzheimer disease (AD).
The US Food and Drug...
07/10/2025
Psych Congress Network
rna strand
News
New Potential Drug Targets for Alzheimer Disease Identified
05/21/2025
Maria Mantas
A recently published study in Nature Communications identified new potential drug targets for the treatment and prevention of Alzheimer disease (AD). 
A recently published study in Nature Communications identified new potential drug targets for the treatment and prevention of Alzheimer disease (AD). 
A recently published study in...
05/21/2025
Psych Congress Network
FDA approval stamp
News
FDA Clears First Blood Test to Help Diagnose Alzheimer Disease
05/19/2025
Meagan Thistle
The FDA has approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, the first blood-based diagnostic tool intended to aid in evaluating Alzheimer disease (AD) pathology.
The FDA has approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, the first blood-based diagnostic tool intended to aid in evaluating Alzheimer disease (AD) pathology.
The FDA has approved the...
05/19/2025
Psych Congress Network
person holding cannabis
Cannabis Use Requiring Acute Care Increases Dementia Risk
04/22/2025
Jolynn Tumolo
People aged 45 years or older with an acute care encounter due to cannabis use had a 3.9-fold higher risk of a new dementia diagnosis within 5 years compared with the general population, according to a recent study.
People aged 45 years or older with an acute care encounter due to cannabis use had a 3.9-fold higher risk of a new dementia diagnosis within 5 years compared with the general population, according to a recent study.
People aged 45 years or older...
04/22/2025
Neurology
From Neurology
Neurons in the brain
News
Risk Factors for Late-Onset Epilepsy in Patients With Cognitive Decline Identified
04/21/2025
Jolynn Tumolo
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk...
04/21/2025
Neurology
From Neurology
A doctor and patient talk
News
Later Life Depressive Symptoms Not Linked With Amyloid Accumulation
03/04/2025
Jolynn Tumolo
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal...
03/04/2025
Psych Congress Network
FDA building
News
FDA Approves Once-Monthly Lecanemab-irmb Dosing for Early Alzheimer Disease
01/28/2025
Meagan Thistle
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
The FDA has approved a...
01/28/2025
Psych Congress Network
US FDA sign
News
Posdinemab Granted Fast Track Designation by the FDA for Early Alzheimer Disease
01/10/2025
Brionna Mendoza
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated...
01/10/2025
Psych Congress Network
a researcher examines MRI scans
News
Diabetes, Amyloid Pathology Linked With Progression to MCI Over 20 Years
01/02/2025
Jolynn Tumolo
Type 2 diabetes and an abnormal amyloid-β concentration in cerebrospinal fluid were associated with accelerated brain atrophy and an earlier progression to mild cognitive impairment (MCI) in a cohort study.
Type 2 diabetes and an abnormal amyloid-β concentration in cerebrospinal fluid were associated with accelerated brain atrophy and an earlier progression to mild cognitive impairment (MCI) in a cohort study.
Type 2 diabetes and an abnormal...
01/02/2025
Neurology
From Neurology

News

A person completes a puzzle of a profile of a head, with a piece missing from where the brain is located.
News
Alzheimer Disease Drugs Show Double the Impact in Long-Term Extension Results
08/05/2025
Jolynn Tumolo
Patients with early Alzheimer disease (AD) treated with lecanemab and donanemab experienced a higher degree of reduced cognitive decline in clinical trial extension studies compared with 18-month results from the core trials.
Patients with early Alzheimer disease (AD) treated with lecanemab and donanemab experienced a higher degree of reduced cognitive decline in clinical trial extension studies compared with 18-month results from the core trials.
Patients with early Alzheimer...
08/05/2025
Neurology
doctor holds clipboard of data and research
News
Limited Demographic Data Transparency Found in Evidence Supporting FDA-Authorized AI Devices for Alzheimer Treatment
07/30/2025
Maria Mantas
Researchers found limited demographic data transparency in the evidence supporting FDA-authorized artificial intelligence (AI)– and machine learning (ML)–enabled medical devices for the treatment of Alzheimer disease and related dementias.
Researchers found limited demographic data transparency in the evidence supporting FDA-authorized artificial intelligence (AI)– and machine learning (ML)–enabled medical devices for the treatment of Alzheimer disease and related dementias.
Researchers found limited...
07/30/2025
Psych Congress Network
FDA approval stamp
News
FDA Approves Modified Titration Dosing for Donanemab-azbt to Reduce ARIA-E Incidence in Early AD
07/10/2025
Maria Mantas
The US Food and Drug Administration (FDA) has approved a label update for donanemab-azbt (Kisunla), Eli Lilly and Company’s monthly intravenous amyloid-targeting therapy for adults with early symptomatic Alzheimer disease (AD).
The US Food and Drug Administration (FDA) has approved a label update for donanemab-azbt (Kisunla), Eli Lilly and Company’s monthly intravenous amyloid-targeting therapy for adults with early symptomatic Alzheimer disease (AD).
The US Food and Drug...
07/10/2025
Psych Congress Network
rna strand
News
New Potential Drug Targets for Alzheimer Disease Identified
05/21/2025
Maria Mantas
A recently published study in Nature Communications identified new potential drug targets for the treatment and prevention of Alzheimer disease (AD). 
A recently published study in Nature Communications identified new potential drug targets for the treatment and prevention of Alzheimer disease (AD). 
A recently published study in...
05/21/2025
Psych Congress Network
FDA approval stamp
News
FDA Clears First Blood Test to Help Diagnose Alzheimer Disease
05/19/2025
Meagan Thistle
The FDA has approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, the first blood-based diagnostic tool intended to aid in evaluating Alzheimer disease (AD) pathology.
The FDA has approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, the first blood-based diagnostic tool intended to aid in evaluating Alzheimer disease (AD) pathology.
The FDA has approved the...
05/19/2025
Psych Congress Network
Neurons in the brain
News
Risk Factors for Late-Onset Epilepsy in Patients With Cognitive Decline Identified
04/21/2025
Jolynn Tumolo
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk...
04/21/2025
Neurology
A doctor and patient talk
News
Later Life Depressive Symptoms Not Linked With Amyloid Accumulation
03/04/2025
Jolynn Tumolo
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal...
03/04/2025
Psych Congress Network
FDA building
News
FDA Approves Once-Monthly Lecanemab-irmb Dosing for Early Alzheimer Disease
01/28/2025
Meagan Thistle
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
The FDA has approved a...
01/28/2025
Psych Congress Network
US FDA sign
News
Posdinemab Granted Fast Track Designation by the FDA for Early Alzheimer Disease
01/10/2025
Brionna Mendoza
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated...
01/10/2025
Psych Congress Network
a researcher examines MRI scans
News
Diabetes, Amyloid Pathology Linked With Progression to MCI Over 20 Years
01/02/2025
Jolynn Tumolo
Type 2 diabetes and an abnormal amyloid-β concentration in cerebrospinal fluid were associated with accelerated brain atrophy and an earlier progression to mild cognitive impairment (MCI) in a cohort study.
Type 2 diabetes and an abnormal amyloid-β concentration in cerebrospinal fluid were associated with accelerated brain atrophy and an earlier progression to mild cognitive impairment (MCI) in a cohort study.
Type 2 diabetes and an abnormal...
01/02/2025
Neurology
An orange prescription container with generic pills spilling out in front of it
News
Antidepressant Use Not Linked to Worse Traumatic Brain Injury Outcomes
02/03/2026
Brionna Mendoza
A large nationwide cohort study found no evidence that preinjury antidepressant use increases short-term mortality, need for emergency brain surgery, or length of hospitalization following TBI.
A large nationwide cohort study found no evidence that preinjury antidepressant use increases short-term mortality, need for emergency brain surgery, or length of hospitalization following TBI.
A large nationwide cohort study...
02/03/2026
Psych Congress Network
A frustrated man works on a laptop
News
Frequent Generative AI Use Linked to Increased Depressive Symptoms
01/23/2026
Maria Mantas
Daily or more frequent generative AI use was associated with higher depressive symptom scores on the PHQ-9 compared with nonuse in a large US survey.
Daily or more frequent generative AI use was associated with higher depressive symptom scores on the PHQ-9 compared with nonuse in a large US survey.
Daily or more frequent...
01/23/2026
Psych Congress Network
a man holds his head in his hands
News
Cohort Study Finds Increased Suicide Risk in Survivors of Traumatic Injury
01/21/2026
Maria Mantas
Patients discharged alive after traumatic injury had a 9-fold higher risk of suicide than the general population 2 years after hospitalization, according to cohort study findings.
Patients discharged alive after traumatic injury had a 9-fold higher risk of suicide than the general population 2 years after hospitalization, according to cohort study findings.
Patients discharged alive after...
01/21/2026
Psych Congress Network
A man looks out a window
News
Adjunctive Vagus Nerve Stimulation Shows Durable Benefit in Treatment-Resistant Depression
01/20/2026
Maria Mantas
A long-term extension study found that adjunctive vagus nerve stimulation (VNS) had a durable benefit in patients with treatment-resistant major depression over 24 months.
A long-term extension study found that adjunctive vagus nerve stimulation (VNS) had a durable benefit in patients with treatment-resistant major depression over 24 months.
A long-term extension study...
01/20/2026
Psych Congress Network
a depressed teen adolescent holds head in hands crying upset sad major depression
News
Omega-3 Supplements Show No Benefit for Pediatric Major Depression in RCT
01/20/2026
Brionna Mendoza
A multicenter randomized clinical trial found that adding omega-3 fatty acid supplements to psychotherapy did not improve outcomes in children and adolescents with moderate-to-severe major depression.
A multicenter randomized clinical trial found that adding omega-3 fatty acid supplements to psychotherapy did not improve outcomes in children and adolescents with moderate-to-severe major depression.
A multicenter randomized...
01/20/2026
Psych Congress Network
brain
News
Several Noninvasive Brain Stimulation Modalities Show Benefit for Treatment-Resistant Schizophrenia
01/19/2026
Maria Mantas
A large network meta-analysis found specific noninvasive brain stimulation (NIBS) modalities improved symptoms in treatment-resistant schizophrenia (TRS).
A large network meta-analysis found specific noninvasive brain stimulation (NIBS) modalities improved symptoms in treatment-resistant schizophrenia (TRS).
A large network meta-analysis...
01/19/2026
Psych Congress Network
US FDA building
News
FDA Requests Removal of Suicide Risk Warnings From GLP-1 RA Labels
01/14/2026
Maria Mantas
The US Food and Drug Administration (FDA) has requested the removal of information regarding the risk of suicidal ideation and behaviors (SI/B) from the labeling of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
The US Food and Drug Administration (FDA) has requested the removal of information regarding the risk of suicidal ideation and behaviors (SI/B) from the labeling of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
The US Food and Drug...
01/14/2026
Psych Congress Network
illustration of a brain
News
Meta-Analysis Confirms Processing Speed as Core Cognitive Deficit in Schizophrenia
01/12/2026
Maria Mantas
Processing speed remains one of the most severely impaired cognitive domains in people with schizophrenia, according to a large systematic review and meta-analysis published in JAMA Psychiatry.
Processing speed remains one of the most severely impaired cognitive domains in people with schizophrenia, according to a large systematic review and meta-analysis published in JAMA Psychiatry.
Processing speed remains one of...
01/12/2026
Psych Congress Network
FDA building
News
FDA Approves At-Home Neuromodulation Therapy Device for Major Depression
01/12/2026
Maria Mantas
The US Food and Drug Administration has approved Proliv™Rx, a novel at-home neuromodulation therapy as adjunctive treatment for adults with major depressive disorder (MDD).
The US Food and Drug Administration has approved Proliv™Rx, a novel at-home neuromodulation therapy as adjunctive treatment for adults with major depressive disorder (MDD).
The US Food and Drug...
01/12/2026
Psych Congress Network
woman on a hill
News
Delay Discounting Fails to Predict Antidepressant Relapse in MDD
01/09/2026
Maria Mantas
A new multi-site study suggests that while delay discounting is elevated in patients with remitted MDD, it neither changes after antidepressant medication discontinuation nor predicts subsequent depressive relapse.
A new multi-site study suggests that while delay discounting is elevated in patients with remitted MDD, it neither changes after antidepressant medication discontinuation nor predicts subsequent depressive relapse.
A new multi-site study suggests...
01/09/2026
Psych Congress Network

Quizzes

quiz
Quiz
Percentage of Patients With Major or Mild Frontotemporal NCD Found With Alzheimer Disease Pathology at Autopsy
07/11/2024
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients...
07/11/2024
Psych Congress Network
Why do hurricanes increase mortality risk in ADRD populations?
Quiz
Why do hurricanes increase mortality risk in ADRD populations?
04/04/2023
Do you remember this study?
Do you remember this study?
Do you remember this study?
04/04/2023
Psych Congress Network
Four pencils with their erasers spelling out "quiz."
Quiz
What strategies can individuals use to reduce their risk of Alzheimer disease?
09/28/2022
Take the quiz to test your clinical knowledge!
Take the quiz to test your clinical knowledge!
Take the quiz to test your...
09/28/2022
Psych Congress Network
a printed test, pencil, and clock on a desk
Quiz
Brain Aging in Schizophrenia
01/22/2026
Maria Mantas
Test your knowledge of recent research with this quick quiz!
Test your knowledge of recent research with this quick quiz!
Test your knowledge of recent...
01/22/2026
Psych Congress Network
An illustration of a pencil marking answers on a quiz sheet
Guidelines Quiz
Medication Monitoring in Patients With BPD
01/20/2026
Brionna Mendoza
Test your knowledge of APA guidelines with this quiz!
Test your knowledge of APA guidelines with this quiz!
Test your knowledge of APA...
01/20/2026
Psych Congress Network
Mark Olfson, MD, MPH
Quiz
Telemental Health Use Patterns
01/16/2026
Maria Mantas
Are you caught up with the latest research on telehealth use patterns?
Are you caught up with the latest research on telehealth use patterns?
Are you caught up with the...
01/16/2026
Psych Congress Network
illustration of a laptop screen displaying a test
Quiz
Stimulants and Psychosis Risk in ADHD
12/22/2025
Maria Mantas
Do you remember the findings from this systematic review?
Do you remember the findings from this systematic review?
Do you remember the findings...
12/22/2025
Psych Congress Network
Joseph Goldberg, MD
Quiz
Diagnosing Mixed Features in Bipolar Disorder
12/03/2025
Joseph F. Goldberg, MD
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
12/03/2025
Psych Congress Network
Pop quiz written on a blackboard with white chalk
Quiz
Depression, Inflammation, and Insomnia
11/19/2025
Brionna Mendoza
Test your knowledge with this quiz!
Test your knowledge with this quiz!
Test your knowledge with this...
11/19/2025
Psych Congress Network
quiz
Quiz
Early Lead Exposure and Mental Health Outcomes
11/10/2025
Maria Mantas
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
11/10/2025
Psych Congress Network
a teenager's hand putting a bag of white pills into another teenager's hand.
Quiz
Test Your Knowledge – Understanding Abuse Potential Across ADHD Therapies: What Clinicians Need to Know
10/23/2025
Curb misuse before it starts—test your diversion-prevention game in 3 quick questions.
Curb misuse before it starts—test your diversion-prevention game in 3 quick questions.
Curb misuse before it...
10/23/2025
Psych Congress Network
Edward Kaftarian, MD
Quiz
Building Patient Rapport in Telepsychiatry
10/09/2025
Edward Kaftarian, MD
Do you remember Dr Kaftarian's recommended strategies for building patient rapport via telehealth?
Do you remember Dr Kaftarian's recommended strategies for building patient rapport via telehealth?
Do you remember Dr Kaftarian's...
10/09/2025
Psych Congress Network
A woman sleeping peacefully
Quiz
Test Your Knowledge – ADHD and Sleep: Why Non-Stimulants Might Be the Right Choice (Part 3)
10/09/2025
Sleep and ADHD intersect—see if your management playbook is up to date in 3 quick questions.
Sleep and ADHD intersect—see if your management playbook is up to date in 3 quick questions.
Sleep and ADHD intersect—see if...
10/09/2025
Psych Congress Network

Perspectives

marc agronin md
Faculty Insights
Alzheimer Disease Prevention: Part 2
07/29/2024
Marc E. Agronin, MD
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated...
07/29/2024
Psych Congress Network
Leslie Citrome, MD, MPH.
Videos
Addressing Agitation in Dementia
11/09/2023
Leslie Citrome, MD
With 7 million individuals living with Alzheimer disease and dementia in the United States, effective home-based strategies are crucial to prevent institutionalization.
With 7 million individuals living with Alzheimer disease and dementia in the United States, effective home-based strategies are crucial to prevent institutionalization.
With 7 million individuals...
11/09/2023
Psychiatry & Behavioral Health
Dr Paul Schulz
Videos
Lecanemab Considerations and Efficacy
10/16/2023
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the...
10/16/2023
Psych Congress Network
Dr Paul Schulz
Videos
Patient Considerations When Prescribing Lecanemab for Alzheimer Disease
09/22/2023
Paul Schulz, MD
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the...
09/22/2023
Psych Congress Network
Dr Paul Schulz
Videos
Advantages and Drawbacks of Lecanemab in Alzheimer Disease Treatment
09/11/2023
Paul Schulz, MD
Dr Paul Shulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Shulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Shulz discusses the...
09/11/2023
Psych Congress Network
Marc Agronin, MD.
Videos
Telepsychiatry Practice for Geriatric Patients
08/11/2023
Marc E. Agronin, MD
In this exclusive video, Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, CMO, describes his experience treating geriatric patients via telehealth.
In this exclusive video, Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, CMO, describes his experience treating geriatric patients via telehealth.
In this exclusive video, Psych...
08/11/2023
Psych Congress Network
Marc Agronin, MD.
Videos
What the Data Tells Us About Telepsychiatry Efficacy and Popularity
07/20/2023
Marc E. Agronin, MD
Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, discusses the meteoric rise of telehealth in mental health care practice.
Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, discusses the meteoric rise of telehealth in mental health care practice.
Psych Congress Network Geriatric...
07/20/2023
Psych Congress Network
Marc Agronin, MD.
Blog
Alzheimer Disease Prevention
08/30/2022
Marc E. Agronin, MD
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Psych Congress Network Section...
08/30/2022
Psych Congress Network
Douglas_Scharre_alzheimers_aducanumab
Videos
Putting Research Into Practice With Aducanumab for Alzheimer Disease
08/27/2021
In this video, Douglas Scharre, MD discusses his presentation “Translating Research Into Practice Everything You Need To Know About Aducanumab But Were Afraid To Ask,” which was given virtually at Neurology Week.
In this video, Douglas Scharre, MD discusses his presentation “Translating Research Into Practice Everything You Need To Know About Aducanumab But Were Afraid To Ask,” which was given virtually at Neurology Week.
In this video, Douglas Scharre,...
08/27/2021
Psych Congress Network
Greg Mattingly, MD
Videos
VMAT-2 Inhibitor Differences and Dosing in Tardive Dyskinesia
01/09/2026
Greg Mattingly, MD
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg...
01/09/2026
Psych Congress Network
Greg Mattingly, MD
Videos
VMAT-2 Inhibitor Differences and Dosing in Tardive Dyskinesia
01/09/2026
Greg Mattingly, MD
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg...
01/09/2026
Psych Congress Network
Steven Chan, MD, MBA
Videos
Digital Mental Health Trends: Policy, Telehealth, and Generative AI
01/07/2026
Steven Chan, MD, MBA
In this video, Psych Congress Steering Committee Member Steven Chan, MD, MBA, FAPA, FAMIA, offers an overview of the most pressing topics in digital mental health.
In this video, Psych Congress Steering Committee Member Steven Chan, MD, MBA, FAPA, FAMIA, offers an overview of the most pressing topics in digital mental health.
In this video, Psych Congress...
01/07/2026
Psych Congress Network
Michael Asbach, DMsc, PA-C
Videos
Differentiating Bipolar II Disorder From Other Psychiatric Conditions
12/08/2025
Michael Asbach, DMSc, PA-C
In this video, Michael Asbach, DMSc, PA-C, walks clinicians through some key clinical considerations for navigating diagnostic ambiguity when assessing patients for bipolar II disorder.
In this video, Michael Asbach, DMSc, PA-C, walks clinicians through some key clinical considerations for navigating diagnostic ambiguity when assessing patients for bipolar II disorder.
In this video, Michael Asbach,...
12/08/2025
Psych Congress Network
Desiree Matthews, PMHNP-BC
Videos
Using Digital Tools to Reduce Clinician Burnout
12/03/2025
Desiree Matthews, PHMNP-BC
In this video filmed at Psych Congress 2025, Steering Committee member Desiree Matthews, PMHNP-BC, discusses the ways in which digital tools can be leveraged to reduce provider burnout.
In this video filmed at Psych Congress 2025, Steering Committee member Desiree Matthews, PMHNP-BC, discusses the ways in which digital tools can be leveraged to reduce provider burnout.
In this video filmed at Psych...
12/03/2025
Psych Congress Network
Craig Chepke, MD, DFAPA
Videos
Comparing Real-World Data on LAIs and Oral Antipsychotics
12/01/2025
Craig Chepke, MD, DFAPA
In this video, Craig Chepke, MD, DFAPA, discusses real-world findings that clinicians should be aware of when considering the use of oral or LAI antipsychotics for schizophrenia treatment.
In this video, Craig Chepke, MD, DFAPA, discusses real-world findings that clinicians should be aware of when considering the use of oral or LAI antipsychotics for schizophrenia treatment.
In this video, Craig Chepke, MD,...
12/01/2025
Psych Congress Network
Timothy Wilens, MD
Videos
Leveraging Digital Therapeutics for ADHD Management
11/14/2025
Timothy Wilens, MD
In this video filmed on-site at Psych Congress 2025, faculty member Timothy Wilens, MD, discusses the role that digital therapeutics may play in the management of attention-deficit/hyperactivity disorder (ADHD).
In this video filmed on-site at Psych Congress 2025, faculty member Timothy Wilens, MD, discusses the role that digital therapeutics may play in the management of attention-deficit/hyperactivity disorder (ADHD).
In this video filmed on-site at...
11/14/2025
Psych Congress Network
Jonathan Meyer, MD
Videos
Updated Approaches to Clozapine Monitoring Post-REMS
11/11/2025
Jonathan Meyer, MD
Filmed at the 2025 Psych Congress, Jonathan Meyer, MD, offers an updated approach for clinicians navigating clozapine monitoring following the end of Risk Evaluation and Mitigation Strategy (REMS) program.
Filmed at the 2025 Psych Congress, Jonathan Meyer, MD, offers an updated approach for clinicians navigating clozapine monitoring following the end of Risk Evaluation and Mitigation Strategy (REMS) program.
Filmed at the 2025 Psych...
11/11/2025
Psych Congress Network
Edward Kaftarian, MD
Videos
Avoiding Legal Gray Areas in Cross-State Telepsychiatry
11/04/2025
Edward Kaftarian, MD
In this video, Psych Congress Steering Committee Member Edward Kaftarian, MD, dives into potential legal gray areas that clinicians may encounter when engaging in cross-state telepsychiatry.
In this video, Psych Congress Steering Committee Member Edward Kaftarian, MD, dives into potential legal gray areas that clinicians may encounter when engaging in cross-state telepsychiatry.
In this video, Psych Congress...
11/04/2025
Psych Congress Network
Timothy Wilens, MD
Videos
Navigating Psychiatric Comorbidities in ADHD
10/17/2025
Timothy Wilens, MD
In this insightful discussion, Psych Congress Faculty Member Timothy Wilens, MD, dissects the challenges clinicians may face when diagnosing and treating common psychiatric comorbidities in individuals with ADHD.
In this insightful discussion, Psych Congress Faculty Member Timothy Wilens, MD, dissects the challenges clinicians may face when diagnosing and treating common psychiatric comorbidities in individuals with ADHD.
In this insightful discussion,...
10/17/2025
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, MSN, APRN, PMHNP-BC
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use